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Malariaa b s t r a c t
Babesia rossi is an important, tick-borne intraerythrocytic protozoan parasite; however, its natural history
and epidemiology is poorly understood. Babesia rossi is the most virulent Babesia sp. in domestic dogs and
is generally considered to cause severe babesiosis, which is fatal if left untreated. However, subclinical
infections and mild disease from B. rossi have been reported, although the clinical progression of these
cases was not reported. Therefore, to better understand B. rossi under field conditions, we evaluated its
clinical progression and seroprevalence in an owned, free-roaming dog population in Zenzele, South
Africa, where the parasite is endemic and prevention is not routine. The entire dog population in
Zenzele was monitored intensively at the individual level from March 2008 until April 2014, primarily
for a longitudinal study on rabies control. Subsequent evaluation of B. rossi comprised analyses of clinical
and laboratory data collected from the Zenzele dog population during the 6 year study period. A substan-
tial proportion (31% (n = 34)) of 109 dogs (randomly selected from every available dog in February/March
2010 older than ~6–8 weeks (n = 246)) tested by Indirect Fluorescent Antibody Test had seroconverted
strongly to B. rossi. All 34 dogs were generally consistently healthy adults, determined from regular clin-
ical examinations between March 2008 and April 2014. Blood smear examinations at multiple time
points between July 2009 and February 2011 were also undertaken for almost all of these (34) seropos-
itive dogs and all those tested were consistently negative for Babesia spp. Subclinical infections and mild
disease were also the main findings for a separate group of 18 dogs positive for Babesia spp. on blood
smear examination and confirmed to be infected with B. rossi by Polymerase Chain Reaction – Reverse
Line Blot. Almost all of these dogs were positive at only one time point from repeat blood smear exam-
inations between July 2009 and February 2011. We suggest that these observations are consistent with
immunity acquired from repeated, low-level exposure to the parasite, generating transient subclinical
infections or mild disease. Should this be the case, the use of tick control, particularly in adult dogs in
free-roaming populations in B. rossi endemic regions, should be carefully considered.
 2020 The Author(s). Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The intraerythrocytic protozoan Babesia rossi is an important
cause of morbidity and mortality in domestic dogs throughout
sub-Saharan Africa (Oyamada et al., 2005; Sasaki et al., 2007;
Schoeman, 2009; Nalubamba et al., 2015; Proboste et al., 2015).
In South Africa, the parasite is transmitted between dogs by the
tick Haemaphysalis elliptica (Apanaskevich et al., 2007;Birkenheuer, 2014) and causes babesiosis in dogs throughout the
year, with incidence peaking during the summer (Shakespeare,
1995; Collett, 2000; Birkenheuer, 2014). The disease occurs mostly
in young dogs and a median age of 15 months has been reported,
although mature dogs can also be affected (Schoeman et al.,
2007; Schoeman, 2009).
Babesia rossi is the most virulent of the Babesia spp. in domestic
dogs, often causing acute and peracute disease with severe clinical
signs including anorexia, depression, weakness, fever, pale mucous
membranes, tachycardia and tachypnoea in infected dogs
(Schoeman and Leisewitz, 2006; Penzhorn, 2011; Leisewitz et al.,
104 M.K. Morters et al. / International Journal for Parasitology 50 (2020) 103–1102019a). Clinical signs are attributed to haemolysis, precipitating
anaemia and tissue hypoxia (Taboada and Lobetti, 2006), and an
excessive pro-inflammatory response (Goddard et al., 2016;
Leisewitz et al., 2019b), leading to hypotension and shock as
described in Babesia canis infections (Matijatko et al., 2009;
Zygner et al., 2014). Thrombocytopenia is also a very frequent find-
ing (Kettner et al., 2003), including in the absence of anaemia
(Taboada and Lobetti, 2006; Birkenheuer, 2014). The disease is
often fatal even with treatment, with approximately 10% mortality
in hospitalised dogs (Schoeman and Leisewitz, 2006; Birkenheuer,
2014). Indeed, infection in dogs left untreated is reported to be
almost invariably fatal (Matjila et al., 2009). However, there are
reports of dogs infected with B. rossi without overt clinical findings
(Matjila et al., 2004; Birkenheuer, 2014), although the clinical pro-
gression of these cases, and treatment provided, was not reported.
Consequently, it is unclear if these subclinical infections were incu-
batory or convalescent, preceding or following fulminant babesio-
sis, or were unassociated with severe babesiosis. Furthermore, the
duration of an (original) infection with B. rossi is unclear. While
‘‘most infectious agents do not have the potential for persistent
infection [chronic carrier state]” (Rothman et al., 2008, p. 551
and p. 559), a chronic carrier state is reported for Babesia spp. in
domestic dogs (Irwin, 2009; Birkenheuer, 2014), although not for
B. rossi specifically. Cases of mild disease from B. rossi have also
been reported; but the clinical and treatment histories of these
cases were also not reported (Adamu et al., 2014).
While the clinical progression of cases of fulminant babesiosis
from B. rossi presented to veterinary facilities for treatment is well
described, the natural history and epidemiology of B. rossi infec-
tions is not. Therefore, to better understand B. rossi infection under
field conditions, we investigated the progression of infections with
the parasite, and its seroprevalence, in an owned, free-roaming dog
population in South Africa, where B. rossi is endemic and tick con-
trol and treatment for babesiosis are not routine.
Note: Only Rothman’s (2008, pp. 551–552; Supplementary
Table S1) definitions for infection, disease and chronic carrier are
used throughout this paper. Acquired immunity refers to ‘‘antigen
specific immunity attributable to the production of antibody and
specific immune T lymphocytes following exposure to an antigen”
(Blood et al., 2007, p. 941); and results from repeated exposure
to the pathogen (Bousema et al., 2014; Fowkes et al., 2016).2. Materials and methods
2.1. Study population
Zenzele is an informal settlement approximately 10 km west of
Johannesburg (2615027.1900S and 2741045.6800E) with an area of
0.72 km2. All of the dogs resident in Zenzele were owned and the
majority were allowed to roam freely. Almost all of the dogs in
the settlement were mixed breed. For the period February 2008–
February 2011, the mean population size for dogs ~8 weeks of
age and older was 323, with a median population size of 321 and
range of 285–362; at least 40% of new dogs were acquired from
outside the community; and 81.6% of new dogs were acquired as
puppies (0–13 weeks of age) (Morters et al., 2014b). Subjectively,
the population size remained within the same range from March
2011 to April 2014. Other than vaccinations against rabies in Octo-
ber 2009 (by the Department of Agriculture, Forestry and Fisheries
[DAFF], South Africa) and February 2010 (by the primary
researcher), the vast majority of the study population did not have
access to veterinary care before May 2011. Some dogs vaccinated
in October 2009 may have received one dose of ivermectin with
the vaccination. From May 2011, charity operated mobile veteri-
nary services have been available in Zenzele.2.2. Overview of data collection and analyses
The entire dog population in Zenzele was monitored inten-
sively at the individual level from March 2008 until April 2014,
primarily for a longitudinal study on rabies control. Details of
the study on rabies control have been published elsewhere
(Morters et al., 2014a,b). To evaluate the clinical progression of
B. rossi infection in dogs in Zenzele, the longitudinal clinical and
laboratory data generated from the rabies control study were
reviewed for two separate groups of dogs whose blood samples
had been stored during the rabies control study and were subse-
quently shown to be positive for exposure to B. rossi. The two
groups of dogs comprised (i) all those positive by Polymerase
Chain Reaction (PCR) – Reverse Line Blot (RLB) in July 2009,
February 2010 and/or February 2011; and (ii) all those positive
by Indirect Fluorescent Antibody Test (IFAT) in February or March
2010. Seroprevalence for B. rossi was also estimated from the sec-
ond group of dogs. The collection and analyses of the clinical and
laboratory data for the rabies control study and analyses of the
stored blood samples for this evaluation of B. rossi are sum-
marised below. Further details are provided in the Supplementary
Methods S1–S3.
2.3. Demographic and clinical data collection
The dog population in Zenzele was highly dynamic, with new
dogs frequently acquired into, and resident dogs lost from, the set-
tlement during the 6 year rabies control study period (from March
2008 until April 2014). During this period, demographic and longi-
tudinal clinical data were collected for each dog in Zenzele for the
entire time it was in the settlement, which includes all of the dogs
reported in this evaluation of B. rossi. The clinical data were col-
lected by physical examination and owner questionnaire during
household visits undertaken about every 7–15 weeks. Medical
records from the mobile veterinary service and owners were
checked from May 2011. See Supplementary Methods S1 for a
detailed description of the demographic and clinical data
collection.
2.4. Blood sample collection and laboratory analyses for the rabies
control study
Blood samples were also collected during household visits. The
sampling regime (i.e. sample size and sampling dates) was also
designed specifically for the rabies control study. See Table 1. Blood
smear examinations, complete blood counts (CBCs) and blood pro-
tein assays were done for all dogs sampled at four time points (July
2009, February 2010, August 2010 and/or February 2011). See Sup-
plementary Methods S2 for a detailed description of blood sample
collection and the laboratory methods for the tests noted above.
The sera from all four time points, as well as from an additional
time point in March 2010, were stored. The whole blood from all
(15) dogs positive for Babesia spp. on blood smear examination
in July 2009, February 2010 and/or February 2011 was stored.
Three other dogs were positive for Babesia spp. on blood smear
examination in August 2010, however their whole blood samples
were inadvertently not stored. Blood samples from the dog used
as the positive control for the IFATs (see Section 2.5) were also
stored.
2.5. Laboratory analyses of the stored blood samples for the evaluation
of B. rossi
All (15) dogs with stored whole blood samples (noted in Sec-
tion 2.4) comprise the first group of dogs listed under Section 2.2.
All 15 samples were tested by PCR-RLB for B. rossi, Babesia vogeli
Table 1
The laboratory analyses used to evaluate the clinical progression and seroprevalence of Babesia rossi in dogs in Zenzele, South Africa.










Number of dogs blood sampled (whole blood and serum) 135a 191b 63c 134d 103d
Number subjected to CBC, blood protein assay & venous blood smear exam 135 191  134 103
Number subjected to capillary blood smear exam 135 ~120   
Number positive for Babesia spp. on blood smear exam (n = 18) 3 8  3 4
Number blood smear positive tested for B. rossi by PCR-RLB 3 8  e 4
Number positive for B. rossi by PCR-RLB 3 8   2f
(see Supplementary Table S4)
Number negative for Babesia spp. on blood smear exam 132 183g  131 99
Number screened for exposure to B. rossi by IFAT (n = 109)h 85 24
Number (strong) positive for exposure to B. rossi by IFAT (n = 34) 28 6
Number borderline strong positive for exposure to B. rossi by IFAT 3 0
(see Supplementary Table S3)
a Random sample (of 135 dogs) taken from every available dog older than ~6–8 weeks of age in Zenzele in July 2009.
b Every available dog (i.e. the entire population) older than ~6–8 weeks of age in Zenzele in February 2010 not vaccinated by the Department of Agriculture, Forestry and
Fisheries (DAFF), South Africa, in October 2009; includes those dogs sampled in July 2009, not vaccinated in October 2009 and still present in Zenzele in February 2010.
c Every available dog vaccinated by the DAFF in October 2009 still present in Zenzele in March 2010. Vaccination by the DAFF was not observed by the primary researcher,
therefore dogs vaccinated by the DAFF were excluded from the rabies control study laboratory analyses (only sera were collected to evaluate antibody responses to the
vaccine, including in March 2010).
d Of the 191 dogs blood sampled (and concurrently vaccinated) in February 2010 by the primary researcher, 134 and 103 dogs were still present in Zenzele in August 2010
and February 2011, respectively, and sampled; therefore, the dogs sampled the February 2010 were also sampled up to three more times (in July 2009, August 2010 and/or
February 2011) according to their availability.
e The whole blood samples for the three dogs blood smear positive in August 2010 were inadvertently not stored by the laboratory. One other dog (Supplementary Table S4,
dog 9) positive for B. rossi by Polymerase Chain Reaction (PCR) – Reverse Line Blot (RLB) in February 2010 was also positive on blood smear examination for Babesia spp. in
August 2010 – the August 2010 whole blood sample for this dog was also inadvertently not stored.
f Very weak positive for the genus Babesia (species not determined) for one sample and no nucleic acid detected for one sample.
g Excludes the eight dogs PCR-RLB positive for B. rossi because the exposure status was already determined by PCR-RLB.
h Random sample of 109 dogs selected from the total pool of 246 (183 dogs in February 2010 and 63 dogs in March 2010 (note: excludes the positive control dog’s March
2010 sample)).
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2004) with a sensitivity of at least 99% for each Babesia sp.
There was no evidence of B. vogeli or B. canis in Zenzele; the sam-
ples tested positive for B. rossi only. This agrees with previous
reports of the geographic distribution of B. vogeli in South Africa
(Matjila et al., 2008), and no reports of B. canis in South Africa.
Therefore, antibodies restricted to B. rossi antigen were measured
by IFAT using the Onderstepoort Veterinary Institute, South Africa,
protocol described in Supplementary Methods S3. To obtain the
second group of dogs listed under Section 2.2, IFATs were under-
taken on a sample of the aforementioned stored sera. The sample
consisted of 109 sera (from 109 dogs), which were randomly
selected from the 183 dogs Babesia spp. negative on blood smear
examination in February 2010 and the 63 dogs vaccinated by the
DAFF in October 2009 still present in Zenzele in March 2010 (see
Table 1). This pool of 246 sera comprised the largest number of
samples available when titres to B. rossi were expected to peak
(at the end of the summer babesiosis season). The arbitrary sample
size of ~100 sera was considered large enough (considering the
exploratory nature of this study) to gauge seroprevalence in
Zenzele.
The negative control for the IFATs was residual serum obtained
from a blood donor dog registered with the Department of Veteri-
nary Medicine, University of Cambridge, UK, who had recently
undergone a standard health check, including routine haematology
and biochemistry, to evaluate fitness for blood donation (Supple-
mentary Table S2). This dog was an 11 year old, female neutered
Labrador that had not travelled outside of the UK, a country where
Babesia spp. affecting dogs are not endemic and where sporadic
cases of B. canis have only recently been recognised in southeastern
England (Fernandez de Marco et al., 2017). The negative control,
owned by a veterinarian, had no clinical history of babesiosis,
was negative for Babesia spp. on PCR and had mostly normal
haematological and biochemical parameters. This dog’s serum con-
sistently fluoresced negative on IFAT, i.e. it had no intraerythro-cytic piriform bodies visible or very dull fluorescence of
intraerythrocytic piriform bodies (Supplementary Fig. S1).
The positive control serum for the IFATs was provided by a
young adult, male mixed-breed dog born in Zenzele in July 2008
(Supplementary Table S2). This dog was diagnosed with severe
babesiosis in November 2009, recovered fully without treatment
and was still present in Zenzele in April 2014. Babesiosis caused
by B. rossi was confirmed by blood smear examination and
PCR-RLB for January 2010. Intraerythrocytic piriform bodies con-
sistently fluoresced (strong) seropositive (i.e. bright apple green;
Supplementary Fig. S2) on IFAT using serum collected at the same
time in January 2010 (when his antibody titre peaked).
The (109) February and March 2010 test sera were first tested in
batches of 10 at 1:40 dilution, i.e. each of the 10 wells on the anti-
gen slide contained the serum of a different dog and the remaining
two wells contained the positive and negative control sera. Thus,
each dog’s serum was tested once at 1:40 dilution for seroconver-
sion to the antigen. In general, any test serum at a 1:40 dilution
that fluoresced more strongly than the negative control was then
tested at a dilution of 1:80. The degree of fluorescence was gauged
at the time of microscopy but subsequently more objectively
determined by careful evaluation of all of the recorded images
for each test serum (at least six high resolution, representative dig-
ital images were recorded for each well, including the control
wells). Only digital image titres are reported in Section 3. Any test
serum that fluoresced at least as intensively as the positive control
at 1:80 dilution on the majority of the digital images was defined
as (strong) seropositive (Birkenheuer, 2014). The degree of fluores-
cence on the digital images was broadly categorised as seronega-
tive (fluorescence  the negative control), weak seropositive,
moderate seropositive, borderline strong seropositive and strong
seropositive (fluorescence  the positive control).
Stored sera belonging to the first group of dogs listed in
Section 2.2 were tested at 1:40 dilution only to determine which
were seronegative.
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Overall, the vast majority of the dogs in Zenzele confirmed as
exposed to B. rossi by IFAT or PCR-RLB were generally consistently
healthy or had transient mild disease as a result. The longitudinal
clinical and laboratory data for each of these exposed dogs are pre-
sented in their entirety in Supplementary Tables S3 and S4 to allow
verification of this finding. The contents of Supplementary Tables
S3 and S4 are summarised below, with reference to the Tables
for specific cases. The group of dogs positive for exposure to B. rossi
by IFAT is reported first; and the group positive on PCR-RLB is
reported second. Note: Normal ranges for haematocrits and plate-
let counts are 0.37–0.55 l/l and 200–500  10^9/l, respectively.
3.1. Seroprevalence and the clinical progression of B. rossi in the dogs
confirmed positive for exposure by IFAT in February and March 2010
The prevalence of dogs seropositive for B. rossi in February and
March 2010 was 31% (34 dogs seropositive (fluorescing at least as
strongly as the positive control at 1:80 dilution against B. rossi anti-
gen) out of a total of 109 dogs tested). All (34) of these dogs also
fluoresced strongly against B. rossi antigen at 1:40 dilution. See
Table 1. From this observation, there is 95% certainty that the true
seroprevalence in the wider population in early 2010 was between
22% and 40% (Kirkwood and Sterne, 2003, p143). The 34 (strong)
seropositive dogs are numbered 1–34 in Supplementary Table S3
(column A). Supplementary Table S3 also shows the date and age
each dog was registered (i.e. first observed in Zenzele) (columns
AO and AP); the date and reason each dog left the study population
or the date it was last evaluated (column AQ); and each dog’s clin-
ical and laboratory findings during the intervening period (col-
umns AS-AU and D-AN, respectively). Note: All of the dogs in
Supplementary Table S3 were acquired as puppies by their owners,
except for dogs 3, 11, 16, 27 and 30 which were acquired as juve-
niles, and dogs 21 and 34 which were acquired as adults.
The majority of the 34 (strong) seropositive dogs were moni-
tored for at least 12 months before, and until at least 7 months
after, blood sampling in February or March 2010. All 34 dogs were
generally healthy throughout the period they were monitored,
with no clinical signs observed or reported consistent with serious
disease caused by B. rossi. Haematocrits and platelet counts were
evaluated in July 2009, February 2010, August 2010 and/or Febru-
ary 2011 for 31 of these (strong) seropositive dogs. Values ranged
between 0.28–0.58 l/l and 137–786  10^9/l, respectively, consis-
tent with no clinical findings of severe babesiosis. Representative
examples of dogs strongly seropositive include dogs 5 and 7, which
were registered in March 2008 as adults, left Zenzele in July 2012
and about September 2013, respectively, were healthy throughout
the intervening period and had normal haematocrits and platelet
counts (and negative blood smear examinations, see below) at all
four time points. Another representative example is dog 3, which
was registered in November 2008 as a juvenile, was present in Zen-
zele in January 2014, had four episodes of non-specific clinical
signs during the intervening period, including slightly pale mucous
membranes in May 2010 and February 2011, and had normal
haematocrits and platelet counts (and negative blood smear exam-
inations) in February 2010, August 2010 and February 2011, except
for a haematocrit of 0.31 l/l in February 2011. The exception to this
overall trend in the data was dog 30, which died in February 2010,
the same month it was blood sampled. A neighbour reported that
dog 30 died of injury, however this could not be confirmed with
the owner. Given the laboratory results in February 2010 (haema-
tocrit 0.30 l/l, platelet count 112x10^9/l and positive for Anaplasma
platys on blood smear examination), the possibility that dog 30
died from a tick-borne disease cannot be ruled out.Thirty-seven dogs (as listed in Supplementary Table S3) were
recorded as (strong) seropositive at the time of microscopy; how-
ever, three of these dogs (dogs 35–37) were subsequently re-
categorised as borderline strong seropositive following careful
examination of their digital images. These three dogs were also
monitored in Zenzele for an extended period (from at least
14 months before, and until 6 months after, being blood sampled
in February 2010). The clinical and laboratory findings for these
(three) dogs are similar to dogs 1–34 discussed above.
Thirty-one of the 37 seropositive dogs were blood sampled in
February 2010 and six were sampled in March 2010. As described
in Section 2.5, all 31 dogs were negative on blood smear examina-
tion for Babesia spp. in February 2010. Blood smears were exam-
ined for blood parasites at least twice for 28 of the 31 dogs
sampled in February 2010 (i.e. 28 dogs were also sampled in July
2009, August 2010 and/or February 2011). All 28 dogs were also
negative for Babesia spp. at all of the other time points (Supple-
mentary Table S3 columns D/E, N/O, X and AG).
Figs. 1 and 2 show the age distribution of the 109 seropositive
and seronegative dogs determined by IFAT, including the 37
seropositive dogs detailed in Supplementary Table S3. No dog was
(strong) seropositive at a dilution of 1:80 below the 11th month
of life. Dogs seronegative at a dilution of 1:40 and, thus, not tested
at a dilution of 1:80 were treated as seronegative in Fig. 1.
3.2. The clinical progression of B. rossi in the dogs confirmed infected
by PCR-RLB in July 2009, February 2010 or February 2011
As noted under Section 2.4, 18 dogs were positive for Babesia
spp. on blood smear examination (see Table 1). Blood smear exam-
ination was undertaken for 11 of the dogs at more than one of the
(July 2009, February 2010, August 2010 and February 2011) time
points and for seven of the dogs at only one of the time points
(Supplementary Table S4 columns D/E, N/O, X and AG). Of the 11
dogs tested at multiple time points, 10 were positive at only one
of the time points and were negative at all other time points tested,
and one dog (Supplementary Table S4, dog 9) was positive at two
of the time points tested. Of the 15 dogs positive for Babesia spp.
on blood smear examination subject to PCR-RLB, 13 were positive
for B. rossi only, one was very weak positive for the genus Babesia
but the species could not be determined and nucleic acid was not
detected for one (Supplementary Table S4 column AO). Poor sam-
ple quality, from prolonged storage (at 80 C) and the small vol-
ume of DNA remaining from the PCR-RLB assays initially
undertaken in June 2012, may have been responsible for the repeat
negative PCR-RLB results in April 2018. Laboratory error is sus-
pected for the negative PCR-RLB results in June 2012. As expected,
most (11) of the dogs were positive on blood smear examination in
the summer, six were positive in the winter and one (dog 9) was
positive in the summer and winter.
The demographic, clinical and laboratory data for each of the 18
dogs positive for Babesia spp. on blood smear examination are
reported in Supplementary Table S4. This includes the date and
age each dogwas registered (i.e. first observed in Zenzele) (columns
AR and AS); the date and reason each dog left the study population
or the date it was last evaluated (column AT); and each dog’s clin-
ical and laboratory findings during the intervening period (columns
AW-AY and D-AP, respectively). Note: All of the dogs listed in Sup-
plementary Table S4 were acquired as puppies by their owners,
except for dogs 11 and 15 which were acquired as juveniles. Over-
all, laboratory and clinical findings for the 18 dogs vary from sub-
clinical infection to fatal babesiosis caused by B. rossi, but are
predominately consistentwith subclinical infection ormild disease.
Fatal babesiosis was confirmed in one juvenile (dog 10) and sus-
pected in one other juvenile (dog 15) and one (probably) very old
Fig. 1. Age distribution of the fluorescence for the 109 dogs from Zenzele, South Africa, from which (109) samples were taken and subjected to immunodiagnostics by IFAT at
a dilution of 1:80. ‘a’ on the X-axis refers to adult dogs that were >52 weeks of age when registered into the study population, so their true age could not be determined by
direct observation.
Fig. 2. Age distribution of the fluorescence for the 109 dogs from Zenzele, South Africa, from which (109) samples were taken and subjected to immunodiagnostics by IFAT at
a dilution of 1:40. ‘a’ on the X-axis refers to adult dogs that were >52 weeks of age when registered into the study population, so their true age could not be determined by
direct observation.
M.K. Morters et al. / International Journal for Parasitology 50 (2020) 103–110 107
108 M.K. Morters et al. / International Journal for Parasitology 50 (2020) 103–110adult (dog 4). All three dogs were positive for B. rossi by PCR-RLB
shortly before their deaths, coinciding with pathognomonic clinical
signs and/or low haematocrits (0.20–0.28 l/l) and platelet counts
(34–114  10^9/l). Three adults (dogs 1, 2 and 5) had transient
clinical signs indicative of mild babesiosis, and dogs 2 and 5 also
had low haematocrits (0.14 and 0.20 l/l) and platelet counts
(~75  10^9/l). These findings coincided with a positive blood
smear for Babesia spp. (but negative PCR-RLB result) for dog 1,
PCR-RLB confirmation of B. rossi for dog 2 and PCR-RLB confirma-
tion for Babesia genus for dog 5; all in February 2011. All three dogs
were monitored for at least 12 months before, and 7 months after,
diagnosis. Other than occasional slightly pale mucous membranes
for dog 2, there were no clinical or laboratory findings consistent
with repeat episodes of babesiosis.
The remaining nine adults and three juveniles were monitored
for several months to years before and after being found positive
for B. rossi by PCR-RLB or (for those dogs sampled in August
2010) positive for Babesia spp. on blood smear examination; with
eight of the dogs monitored for at least 6 months before, and nine
for at least 6 months after, diagnosis. During their observation peri-
ods, all 12 dogs had either no clinical signs or non-specific, mostly
occasional clinical signs, including slightly pale mucous mem-
branes for three of the dogs. These clinical signs occurred at the
same time point as a positive PCR-RLB for B. rossi or blood smear
examination for Babesia spp. for only two dogs (8 and 9). Haemat-
ocrits and platelet counts corresponding to the time points the
dogs were positive on PCR-RLB or blood smear ranged from 0.17-
0.40 l/l and 33-280x10^9/l, respectively. Seven of the (12) dogs
were blood sampled at more than one of the four time points. Hae-
matocrits and platelet counts corresponding to the time points the
dogs were negative on blood smear ranged from 0.27–0.51 l/l to
74–772  10^9/l, respectively, but were mostly normal. Of note
is dog 12, which had an apparently subclinical infection of B. rossi.
This dog was registered in the study population as an adult 2 years
prior to testing positive for B. rossi on PCR-RLB in February 2010,
was still present in the study population in December 2013, had
no clinical findings consistent with babesiosis throughout the
intervening period, had normal haematocrits and platelet counts
(other than a haematocrit of 0.31 l/l in February 2011) and nega-
tive blood smear examinations for Babesia spp. in July 2009, August
2010 and February 2011.
Of the dogs evaluated for seroconversion to B. rossi by IFAT at a
dilution of 1:40 (Supplementary Table S4 column AP), the three
dogs (16, 17 and 18) positive for Babesia spp. on blood smear
examination in August 2010 that were not tested by PCR-RLB were
(strong) seropositive (in August 2010); and three dogs (6, 10 and
13) PCR-RLB positive for B. rossi did not seroconvert or mounted
only a weak humoral response to infection. Of these, the juvenile
dog 10 was positive for B. rossi by PCR-RLB and had a haematocrit
of 0.28 l/l and platelet count of 37  109/l on 9 February 2010, but
had no clinical findings of babesiosis and was negative by IFAT at
this time point. By mid-March, this dog had developed severe
babesiosis but was only moderately seropositive shortly before
being euthanized upon clinical deterioration. Similarly, the adult
dog 6 tested positive for B. rossi by PCR-RLB and had a parasitaemia
of 3+ (i.e. approximately 3% parasitaemia) by blood smear exami-
nation in February 2010 but was simultaneously negative by IFAT
and had no clear clinical findings of babesiosis throughout the
3 years it was monitored.
3.3. Treatment provided by the mobile veterinary services from May
2011
Thirty-seven dogs, including the positive control dog, were still
present in Zenzele in May 2011 (Supplementary Tables S2, S3 col-
umn AQ and S4 column AT). According to the owner, dog 28 in Sup-plementary Table S3 was diagnosed with Babesia spp. infection by
the mobile veterinary services in February 2012; however, there is
no clinic record of this or that the dog received any treatment from
the mobile clinic. No other dog reported in Supplementary Tables
S3 and S4 was diagnosed with or treated for Babesia spp. infection
by the mobile veterinary services from owner reports and clinic
records.
Occasional tick prophylaxis was provided for some of the 37
dogs while they were still present in Zenzele from May 2011 until
April 2014. Ten dogs were treated once with topical permethrin
and two of these dogs were treated again, 1–2 months after the
first dose. Seventeen dogs received one dose of ivermectin; six of
these dogs received one more dose and three received two more
doses. The interval between doses of ivermectin varied from one
to about 11 months. With one exception, permethrin was given
at the same time as ivermectin.3.4. Frequency of tick infestations
In general, ticks were a very common finding on examination
throughout the study period, with ticks observed at least once
for 89% of the borderline strong and strong seropositive and 84%
of the negative to moderate seropositive dogs examined (Fig. 1).4. Discussion
The longitudinal clinical and laboratory data and blood samples
collected for the rabies control study in Zenzele between March
2008 and April 2014 were sufficient to allow a reasonably compre-
hensive clinical picture of B. rossi in the free-roaming dogs in the
settlement to be generated retrospectively. Although the design
of the rabies control study constrained the laboratory data to four
time points, in combination with the longitudinal clinical data we
observed a range of clinical and laboratory findings in dogs
exposed to B. rossi in Zenzele, the majority consistent with subclin-
ical infection and mild disease in adult dogs. This is a novel finding,
contrary to the prevailing view that infection with B. rossi is invari-
ably highly virulent.
One possible explanation for our observations is that the major-
ity of the mature dogs in our study population had acquired immu-
nity to B. rossi through repeated, low-level exposure to the parasite
from a young age. We suggest immunity to B. rossi acquired
through repeated, transient infections for several reasons. Firstly,
acquired immunity has been observed under experimental condi-
tions for B. rossi (Lewis et al., 1995) and B. vogeli (Brandao et al.,
2003) and under field conditions for B. canis (Martinod et al.,
1985). Secondly, it is well established that humans in malaria
endemic areas acquire immunity to Plasmodium spp. through
repeated exposure to the pathogen (Langhorne et al., 2008;
Doolan et al., 2009; Bousema et al., 2014; Fowkes et al., 2016;
Triller et al., 2017); and Plasmodium spp. are virulent, intraerythro-
cytic protozoa comparable to B. rossi. And thirdly, the resultant epi-
demiological picture of malaria in endemic regions is similar to
that for B. rossi in Zenzele.
In malaria endemic regions, non-sterilising acquired immunity
to the parasite increases with age, from repeated exposure to the
pathogen and the establishment of immunological memory
(Langhorne et al., 2008; Doolan et al., 2009; Bousema et al.,
2014; Fowkes et al., 2016). Consequently, severe disease from
malaria primarily affects young children, with an estimated case
fatality rate of 2% in African children under 5 years of age
(Doolan et al., 2009). While immune individuals in malaria ende-
mic areas are generally continually parasitaemic from continual
re-infection, ‘‘in the absence of continual exposure solid immunity
against severe disease is apparently relatively short lived” (Doolan
M.K. Morters et al. / International Journal for Parasitology 50 (2020) 103–110 109et al., 2009 p. 14 and p. 17). Similarly, in Zenzele repeated exposure
to B. rossi and the acquisition of immunity with age is plausible.
With respect to repeated exposure, the vast majority of dogs resi-
dent in Zenzele (including those reported in this study) were
acquired as puppies by their owners (Morters et al., 2014b) and
ticks were commonly found during the physical examinations;
confirmed by the observed seroprevalence, which shows a large
(31%) proportion of the dog population had been bitten by infected
ticks (probably also recently given the strength of seroconversion).
On this basis, it is unlikely the seronegative adult dogs reported in
this study were never exposed to the parasite. Titres may have
waned in these dogs through lack of recent exposure, with an
anamnestic immune response expected following re-infection.
With respect to age-related immunity, mature dogs reported in
this study were apparently unaffected, or not seriously affected,
by exposure to B. rossi; none of the (34) dogs (strong) seropositive
to B. rossi were young juveniles (Figs. 1 and 2); and fatal babesiosis
was suspected only in young juveniles (Supplementary Table S4,
dogs 10 and 15) and what may have been a very old dog (Supple-
mentary Table S4, dog 4), consistent with the aforementioned gen-
eral literature (Schoeman et al., 2007; Schoeman, 2009).
With respect to possible drivers of acquired immunity to B. rossi
in dogs, the seasonal trough in exposure to B. rossi might act as a
driver, with challenge from the pathogen during the winter
months being sufficient to induce immunity but insufficient to
induce clinical disease (Doolan et al., 2009). Concomitant acquired
immunity to the ticks and/or grooming might also disrupt trans-
mission and, thus, reduce the number of sporozoites transmitted
per tick bite (Martinod et al., 1985). Lastly, given that female adult
dogs in free-roaming dog populations do not routinely receive tick
prophylaxis, protection from maternally derived antibody, boost-
ered through concurrent environmental exposure culminating in
life-long acquired immunity, should be considered.
Our observations further suggest that infections with B. rossi in
Zenzele were transient, consistent with Rothman’s view (Rothman
et al., 2008, p. 559); rather than persistent in the absence of re-
exposure, indicative of a chronic carrier state (as defined by
Rothman et al., 2008, p. 551). Firstly, the 31 seropositive dogs also
tested for Babesia spp. by blood smear examination were consis-
tently negative on blood smear examination across multiple time
points, including at the time they were seropositive in February
2010 (Supplementary Table S3). Given that blood smear examina-
tion detects parasitaemia as low as 0.0002% (Woolley et al., 2017),
and the expertise of the laboratory staff, it is highly likely these
dogs were not infected with Babesia spp. when they were tested,
rather than being persistently infected with infection being persis-
tently missed. Similarly, all of the dogs that were positive for Babe-
sia spp. by blood smear examination were only ever positive at one
of multiple time points tested (Supplementary Table S4). The only
exception was dog 9, where re-infection between successive (blood
smear positive) time points could have occurred. As discussed
above, an effective immune response rapidly clearing infection
upon re-exposure (including shortly before February 2010) cannot
be discounted. Nonetheless, blood smear examination was limited
to up to four time points, with an interval of at least 6 months
between time points; the dogs listed in Supplementary Table S3
were not tested by PCR-RLB which is more likely to detect B. rossi
(Takeet et al., 2017; Woolley et al., 2017), either viable organisms
or residual break-down products following infection; and varia-
tions in titres with time and laboratory and clinical findings was
not evaluated; therefore a chronic carrier state cannot be ruled
out. Conversely, purported chronic carrier states are generally
associated with convalescence (Goering et al., 2013). The high
prevalence (31%) of (strong) seroconversion to B. rossi in Zenzele
suggests that if this were the case, a large fraction of the dog
population survived severe babesiosis to develop a convalescentcarrier state. This scenario suggests persistent infection generates
strong humoral responses for up to 2 years (between registration
into the study population in March 2008 and immunodiagnostics
undertaken in February 2010). For the parasite to have persistently
replicated at levels below microscopic detection but sufficient to
stimulate continually strong humoral responses following recovery
from severe disease before March 2008 may be less plausible than
acquired host immunity rapidly clearing re-infections which
occurred after registration. In this respect also, our findings do
not provide clear evidence of ‘‘a chronic carrier state which occurs
when the host is cured of disease but has persistent infection and
the infectious agent continues to replicate leading to continued
infectiousness”; with infection defined as when ‘‘an agent is pre-
sent in host tissues without signs, symptoms or laboratory evi-
dence of tissue damage” (Rothman et al., 2008, p. 551 and p. 552).
Alternative explanations for B. rossi causing subclinical infection
and mild disease should also be considered, not least because of
laboratory findings consistent with mild babesiosis in three juve-
niles in Zenzele infected with B. rossi (Supplementary Table S4,
dogs 7, 13 and 16). The prognosis of B. rossi infections requiring
treatment varies with the genotype of the species (Matjila et al.,
2009) and breed of dog (Reyers et al., 1998; Mellanby et al.,
2011). Both of these factors may contribute to the mixed picture
of infection by B. rossi in populations. Firstly, the prognosis of ful-
minant babesiosis from B. rossi in dogs in South Africa has been
associated with the genotype of the erythrocyte membrane antigen
gene (BrEMA1) (Matjila et al., 2009); and the absence of the
BrEMA1 gene has been associated with mild babesiosis from B.
rossi in dogs in Nigeria (Adamu et al., 2014). However, the absence
of the BrEMA1 gene from B. rossi has yet to be demonstrated in
South Africa in order to differentiate acquired immunity from
genotype as the cause of mild disease. Secondly, the predominantly
mixed breed dogs in Zenzele may be genetically less prone to sev-
ere babesiosis from B. rossi than the pure and first cross breed dogs
often presented to clinicians with severe babesiosis (Mellanby
et al., 2011; Liu et al., 2017).
In conclusion, our observations warrant two important future
lines of enquiry regarding the natural history and epidemiology
of B. rossi infection in owned, free-roaming dog populations in
endemic regions where babesiosis is not routinely prevented. The
first is the role of repeated exposure generating acquired immunity
against the pathogen, attenuating the severity and duration of
infection. Should this prove to be the case, we may also learn from
observations of control measures such as insecticides in malaria
endemic regions where reductions in exposure to Plasmodium
spp. to below levels necessary to maintain acquired immunity
resulted in serious rebound epidemics (Romi et al., 2002; Doolan
et al., 2009). Consideration should be given to the effect of reduc-
tions in acquired immunity through the widespread use of tick
prophylaxis in mature free-roaming dogs. Equally, the value of
sub-therapeutic tick prophylaxis in dogs with acquired immunity
to B. rossi should also be considered; not least because from May
2011 27% of the (37) dogs positive for Babesia spp. on blood smear
examination and immunodiagnostics, including the positive con-
trol, still present in Zenzele had received at least one dose of topi-
cal permethrin and 46% had received ivermectin subcutaneously at
least once. The second important line of enquiry is with regard to
the absence of the BrEMA1 and related genes from B. rossi in South
Africa and its association with the clinical progression of babesio-
sis. The absence of the BrEMA1 gene may prove to be indicative of
the prognosis for B. rossi infections in general.
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